- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00288392
Efficacy of Soluble Beta-1,3/1,6-Glucan Compared to Placebo on Chronic Leg Ulcers in Diabetes Patients
A Double-Blind Therapeutic Exploratory Clinical Study to Evaluate the Efficacy of Soluble Beta-1,3/1,6-Glucan Compared to Placebo on Chronic Leg Ulcers in Diabetes Patients
The purpose of this study is to evaluate the efficacy of soluble beta-1,3/1,6-glucan compared to placebo on the healing of chronic leg ulcers in diabetes patients.
Hypothesis: Through its ability to activate tissue macrophages and counteract diabetes-associated defects in macrophages, the soluble beta-1,3/1,6-glucan will promote the healing of leg ulcers in diabetic patients.
Study Overview
Detailed Description
Diabetes predisposes to ulceration of the foot through a variety of processes, including neuropathy and peripheral arterial disease. Once the skin is broken, healing is frequently delayed and the ulcer develops the biology of a chronic wound. The factors underlaying delayed healing in chronic wounds are not well understood but include the effects of repeated trauma, tissue ischemia, infection, defective white cell function, altered immune processes, and altered expression of tissue cytokines and enzymes.
Management is based on regular cleansing and debridement, off-loading and treatment of intercurrent infection with antibiotics. There are no interventions in routine use, which target aspects of chronic wound biology directly.
Study Type
Enrollment
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Arkhangelsk, Russian Federation, 163061
- Municipal Healthcare Institution 1st City Clinical Hospital
-
St. Petersburg, Russian Federation, 195257
- St. Petersburg State Institution Saint Martyr Elezabeth Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Type 1 or Type 2 diabetes mellitus
- Age>= 18 years
- Study wound is a Wagner Grade 1 partial thickness or Grade 2 full thickness lesion but without exposed tendon, joint, or bones
- Study wound located on the foot or lower leg
- Study wound must have been present for at least 4 weeks prior to Day 0 but not longer than 2 years
- Adequate circulation to the foot, evidenced by a palpable pulse on the study foot
- Study wound > 1.0cm2 but < 20.0cm2
- Written informed consent
Exclusion Criteria:
- Pregnancy, lactation or absence of adequate contraception for fertile women
- Ankle/Brachial Index < 0.7
- Severe malnutrition
- Clinical evidence of gangrene on any part of the foot with the study wound
- Active or extensive cellulitis extending more than 1 cm beyond wound margin and/or presence of cellulitis with purulent discharge on day 0
- One or more medical condition(s) that in the opinion of the investigator would make the patient an inappropriate candidate for the study
- Active osteomyelitis of the foot with the study wound
- Necrotic toes on the foot with the study wound
- Surgical procedure (other than debridement) on the foot with the study wound the last 21 days prior to screening
- Study wound over a Charcot's joint
- Evidence of deep tissue infection of the study wound at day 0
- Non-study wound on the study foot that is located within 5.0cm from the study wound at day 0
- Random blood sugar reading > 450 mg/dL
- Alcohol or drug abuse
- Participation in other clinical studies in the last 4 weeks
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
- Time to healing
|
Secondary Outcome Measures
Outcome Measure |
---|
Safety
|
Number of patients with complete healing of treated ulcers after 12 weeks of treatment
|
Percentage reduction in ulcer area of treated ulcers after 12 weeks of treatment
|
Percentage weekly reduction in ulcer area in treated ulcers
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Tatyana Zykova, Dr.med., Municipal Healthcare Institution 1st City Hospital, Department of Endocrinology
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SBG-1-11
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Foot Ulcer
-
Zagazig UniversityCompletedUlcer Foot | Chronic Skin Ulcer | Non-Healing Ulcer of SkinEgypt
-
University of PittsburghSociety for Vascular SurgeryTerminatedIschemic Foot UlcerUnited States
-
University of MinnesotaRecruitingDiabetes Mellitus | Foot Ulcer | Ulcer | Diabetic Foot Ulcer | Foot Ulcer, Diabetic | Ulcer Foot | Ulcer, Leg | Ankle UlcerUnited States
-
University of CreteCompletedIschemic Foot Ulcers
-
University of MessinaCompletedDiabetic Ulcer | Foot Ulcer UnhealedItaly
-
Karolinska InstitutetCompleted
-
ETS Wound Care, LLCProfessional Education and Research InstituteCompletedDiabetic Foot | Diabetic Foot Ulcer | Ulcer FootUnited States
-
University College of Southeast NorwayVestre Viken Hospital TrustUnknown
-
National and Kapodistrian University of AthensTerminatedDiabetic Foot | Chronic Diabetic Foot Ulcer of Right Foot | Neuropathic Foot Ulcer | Chronic Diabetic Ulcer of Left Foot (Diagnosis)Greece
-
Holbaek SygehusCompletedDiabetic Foot | Diabetic Foot Ulcer | Ulcer Foot | Ulcer Healing | Wound Healing DisorderDenmark
Clinical Trials on Soluble beta-1,3/1,6-glucan
-
Biotec Pharmacon ASATerminated
-
Biotec Pharmacon ASACompletedOral MucositisGermany, United Kingdom
-
Imuneks Farma ilac San. Tic. A.S.TC Erciyes UniversityCompleted
-
Fakultas Kedokteran Universitas IndonesiaUnknown
-
University of BrawijayaPT. Sahabat Lingkungan HidupEnrolling by invitation
-
Al-Azhar UniversityCompletedLocalized Aggressive Periodontitis
-
Meiji University of Oriental MedicineKyoto Prefectural University of MedicineTerminatedAllergic ConjunctivitisJapan
-
Biotec Pharmacon ASACompletedChronic Diabetic Foot UlcersUnited Kingdom
-
Fakultas Kedokteran Universitas IndonesiaUnknown